Hengrui Pharma(SH:600276) Ge Long Hui A P P·2025-05-14 23:20Group 1 - The company, Heng Rui Medicine, plans to globally issue approximately 225 million H-shares, with 12.3486 million shares available in Hong Kong and around 212 million shares for international offering [1] - The expected pricing date for the shares is May 21, 2025, with a price range of HKD 41.45 to HKD 44.05 per share [1] - The company has established a cornerstone investment agreement, with cornerstone investors agreeing to subscribe for shares totaling USD 533 million (approximately HKD 4.131 billion) [3] Group 2 - The company is recognized as a leading innovative pharmaceutical enterprise rooted in China, ranking highly in terms of innovative drug revenue and the number of new drug entities in clinical or later stages [2] - The company has committed to significant R&D investment, with 29.4% of total revenue allocated to R&D in 2024 [2] - The net proceeds from the global offering are expected to be approximately HKD 94.578 billion (assuming a mid-price of HKD 42.75 per share) or HKD 125.282 billion if the overallotment option is fully exercised [4] Group 3 - The company intends to allocate approximately 45% of the net proceeds for clinical research of innovative and pipeline drugs, 20% for the development of innovative drugs, and 10% for potential global acquisitions and collaborations [4] - Additionally, around 15% of the funds will be used for building new production and R&D facilities in China and overseas, with the remaining 10% for working capital and other general corporate purposes [4]